| Bioactivity | Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively[1]. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis[2]. | ||||||||||||
| Invitro | Famitinib inhibits the VEGF-induced proliferation, migration and tubule formation of human umbilical vein endothelial cells, and micro-vessel spouting from matrigel-embedded rat aortic rings[1].Famitinib (1.8 and 3.6 μM; 48 h) inhibits cell proliferation by inducing cell cycle arrest at the G2/M phase and causes cell apoptosis in a dose-dependent manner in gastric cancer cell lines[2].Famitinib (0.6-20.0 µM; 24-72 h) inhibits gastric cancer cell growth in a dose-dependent manner[2]. Cell Proliferation Assay[2] Cell Line: | ||||||||||||
| Name | Famitinib | ||||||||||||
| CAS | 1044040-56-3 | ||||||||||||
| Formula | C23H27FN4O2 | ||||||||||||
| Molar Mass | 410.48 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Famitinib
CAS: 1044040-56-3 F: C23H27FN4O2 W: 410.48
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.